San Diego-based Dexcom reported a 30 percent year-over-year revenue increase in quarter one results due a sharp increase in international sales.

Revenue for the quarter was $184.4 million, beating a prediction of $172.7 million from a Zacks survey of 11 analysts. Dexcom makes diabetes monitoring devices.

Net loss came to $24.2 million, or $0.28 loss per share, compared to a net loss of $41.7 million, or $0.49 loss per share, for the same quarter in 2017. Those figures reflect Generally Accepted Accounting Principles, or GAAP.

In late March, the U.S. Food and Drug Administration signed off on Dexcom’s G6 diabetes monitoring system, which doesn’t require finger prick blood draws for calibration.

Dexcom’s stock closed at $74.31 a share, hitting $77.76 in after-hours trading as of 3:15 p.m.